Articolul precedent |
Articolul urmator |
458 8 |
Ultima descărcare din IBN: 2024-02-11 13:04 |
SM ISO690:2012 RUSSU, Irina, AVRICENCO, Mariana, HOLBAN, Tiberiu. Reacțiile adverse la tratamentul antiviral al pacienților cu hepatită virală C cronică. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 181. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | |||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | |||||
|
|||||
Pag. 181-181 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Background. Treatment of chronic VHC with direct-acting antiviral drugs has an advantage over treatment with PEG-INF and ribavirin, due to the possibility of oral administration, short duration of treatment, obtaining a sustained virological response in about 95% of cases and minimal side effects. Objective of the study. Analysis of side effects and complications after treatment with directacting antiviral drugs compared to PEG-INF and ribavirin in patients with chronic HCV. Material and Methods. The study was performed in 198 patients with chronic viral hepatitis C who followed two antiviral treatment regimens. Patients in group I (n = 103) received antiviral treatment with sofosbuvir + ledipasvir orally for 12 weeks, those in group II (n = 95) - intramuscular PEG-INF + ribavirin orally for 48 weeks. Results. Our study showed that treatment of chronic VHC with sofosbuvir and ledipasvir was well tolerated, 12,6% of patients had minor side effects: asthenia and headache – 3,9%, insomnia – 2,9%, nausea - 1.9 %. No patient required discontinuation of treatment. During treatment with PEG-INF and ribavirin, fever and other signs of general intoxication showed 80% patients, asthenia – 58,9%, headache – 48,4%, nausea – 39,9%, insomnia – 36,8% , rash – 24,5%, depression – 22,1%, weight loss – 9,5%, alopecia – 7,37%, anemia – 54,7%, leukopenia – 76,8%, thrombocytopenia - 34,7% patients. Conclusion. Our study showed that treatment with sofosbuvir + ledipasvir was well tolerated and had a significantly lower number of side effects and complications compared to PEG-INF and ribavirin treatment. |
|||||
Cuvinte-cheie VHC, treatment, sofosbuvir, ledipasvir, PEG-INF, ribavirin, HVC, Tratament, sofosbuvir, ledipasvir, PEG-INF, ribavirină |
|||||
|